TIGIT Inhibitors – Market Opportunity, Pipeline & Competitive Intelligence 2020

This TIGIT report covers the TIGIT market opportunity providing Key Competitive Analysis, 15+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc)
 
NEW DELHI - Nov. 24, 2020 - PRLog -- The T cell immunoglobulin checkpoint and ITIM domain (TIGIT) has gained a lot of attention in recent years due to the number of roles it plays in different malignant tumors. It is also called WUCAM, Vstm3, VSIG9 and interacts with CD155 expressed on antigen presenting cells or tumor cells to downregulate the functions of T and natural killer (NK) cells.
TIGIT has emerged as a key inhibitor of anti-tumor responses that can hinder multiple stages of the cancer immune cycle. The precise mechanism of action remains unclear and may have both cell-intrinsic and cell-extrinsic components; it can, for example, prevent NK from releasing tumor antigens cells, alter the priming of T cells by DCs or inhibit the killing of cancer cells by CD8+ T cells. The expression of TIGIT frequently occurs in parallel with the expression of other co-inhibitory receptors, in particular PD-1, where it acts synergistically to regulate the antitumor response.

The diverse function of TIGIT in multiple cell types has made it a profitable candidate for immunotherapy, with an increasing number of candidates being studied in preclinical and clinical settings. Preclinical studies have indicated that TIGIT blockade can protect against various solid and hematological cancers. Several monoclonal antibodies (mAbs) have been developed that block the inhibitory activity of human TIGIT. Studies combining antibodies against TIGIT with ICI of the PD-1 / PD-L1 pathway have become particularly interesting in light of the data showing the co-expression of TIGIT and PD-L1 in many types of cancer. Clinical trials are underway studying TIGIT blockade alone or in combination with PD1 / PD-L1 antibodies for the treatment of patients with advanced solid tumors.

The mechanism has piqued the interest from Merck and Roche, with the latter having the most advanced candidate, tiragolumab. There are more than 15 companies exploring their candidates. This report covers the TIGIT Market Opportunities (https://mellalta.com/case-study/finding-and-rewarding-the...) by providing Key Competitive Analysis, 15+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc), Licensing and Agreements, Business Agreement, business partner, Clinical Agreement, 2020 earnings call update, market launch preparation, marketing strategy, future agenda and upcoming events.

Key Takeaways from the Report

• Indication Prioritisation: TIGIT market potential based on Indications
Business Transactions & Strategies: Key collaborations and deal values
TIGIT Pipeline Development: Product Profiles, Clinical Trials & Results
TIGIT Acquisition Targets
TIGIT Competitive Intelligence
• Recent & Upcoming events

Contact us: bd@mellalta.com
Visit: www.mellalta.com

Contact
Emma Stone
***@mellalta.com
End
Email:***@mellalta.com Email Verified
Tags:Tigit Inhibitors
Industry:Health
Location:New Delhi - Delhi - India
Subject:Products
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Mellalta Meets News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share